Amarin Corp Plc (AMRN)

[ziploc_1]

With a successful R-IT, the FDA would approve Vascepa as an add on to a statin for patients with 200 TG or more. Amarin started the study with 150 TG or more in order to widen the indication as much as possible, but then, fearing that there wouldn't be enough timely events, they raised the level for the study to 200 TG. If we are correct, the lowering of TG's is not as important as the anti-inflammatory effects of Vascepa. If Amarin had available to them all the current information at that time, Amarin could have left the level at 150TG.